NIH conference. New approaches to the immunotherapy of cancer using interleukin-2.
about
Intravenous ascorbic acid as an adjuvant to interleukin-2 immunotherapyPretreatment with FK506 improves survival rate and gas exchange in canine model of acute lung injury.Acute pancreatitis associated with high-dose interleukin-2 immunotherapy for malignant melanomaPriming of tumor-specific T cells in the draining lymph nodes after immunization with interleukin 2-secreting tumor cells: three consecutive stages may be required for successful tumor vaccination.Cancer vaccines: the interleukin 2 dosage effectCancer immunogene therapy: a review.Evidence for cytokine-inducible nitric oxide synthesis from L-arginine in patients receiving interleukin-2 therapyClinical and immune modulatory effects of alternative weekly interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma and melanomaImmunological effects of alternative weekly interferon-alpha-2b and low dose interleukin-2 in patients with cancer.Strategies for improving antitumor activity utilizing IL-2: preclinical models and analysis of antitumor activity of lymphocytes from patients receiving IL-2.Central nervous system toxicity of biological response modifiers.Impaired left ventricular filling rate induced by treatment with recombinant interleukin 2 for advanced cancer.Aspergillus fumigatus contamination of lymphokine-activated killer cells infused into cancer patients.Immunotherapy of renal cell cancer.Prolonged interleukin-2 (IL-2) treatment can augment immune activation without enhancing antitumor activity in renal cell carcinoma.Bronchoalveolar lavage and the immunology of lung cancer.Cancer, cytokines, and cytotoxic cells: interleukin-2 in the immunotherapy of human neoplasms.The mixed human umbilical cord blood-derived mesenchymal stem cells show higher antitumor effect against C6 cells than the single in vitro.Clinical chorioamnionitis at term IV: the maternal plasma cytokine profile.Innate anti-breast cancer immunity of apoptosis-resistant human gammadelta-T cells.Medical management of stage IV malignant melanoma. Medical issues.Salvage immunotherapy with subcutaneous recombinant interleukin 2 (rIL-2) and alpha-interferon (A-IFN) for stage D3 prostate carcinoma failing second-line hormonal treatment.C1-inhibitor substitution therapy in septic shock and in the vascular leak syndrome induced by high doses of interleukin-2.Monitoring of immunotherapy with cytokines or monoclonal antibodies.Autohaemotherapy after treatment of blood with ozone. A reappraisal.Minimal toxicity during protein A immunoadsorption treatment of malignant disease: an outpatient therapy.The influence of autologous lymphokine-activated killer cell infusions on the toxicity and antitumor effect of repetitive cycles of interleukin-2.Intestinal epithelial function: the case for immunophysiological regulation. Implications for disease (2).Interleukin-2: use in solid tumors.Altered expression of P-glycoprotein and cellular adhesion molecules on human multi-drug-resistant tumor cells does not affect their susceptibility to NK- and LAK-mediated cytotoxicity.First place--Resident Clinical Science Award 1990. Suppression of lymphokine-activated killer cell cytotoxicity by a soluble factor produced by squamous tumors of the head and neck.T cell-mediated lethal shock triggered in mice by the superantigen staphylococcal enterotoxin B: critical role of tumor necrosis factor.CD134/CD137 dual costimulation-elicited IFN-γ maximizes effector T-cell function but limits Treg expansion.Asbestos fibres inhibit the in vitro activity of lymphokine-activated killer (LAK) cells from healthy individuals and patients with malignant mesothelioma.A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma.Immunogene therapy using immunomodulating HVJ-E vector augments anti-tumor effects in murine malignant glioma.Inpatient continuous-infusion interleukin-2 in 788 patients with cancer. The National Biotherapy Study Group experience.Treatment with allogeneic interleukin-2 secreting fibroblasts protects against the development of malignant brain tumors.Targeted superantigens for immunotherapy of haematopoietic tumours.Application of interleukin-2-secreting syngeneic/allogeneic fibroblasts in the treatment of primary and metastatic brain tumors.
P2860
Q27027097-E591ED21-A28A-406A-96CB-E9C1FD4806B7Q32032833-7A3A9115-BF55-42A8-BF55-16EB408FC530Q33558311-47385FB3-1C0B-44AB-9943-9EA99566F1E7Q34235329-26F5D297-C80C-4E0A-9FAE-26482665449FQ34361454-F15C0D07-96BA-4EF8-BADE-23DFCC240708Q35059588-E267E450-FB15-4A9E-8C24-BE04DA8932EFQ35599161-56628706-CE15-4AB8-8175-1B2C9A84DF26Q35982970-6CE989BD-3307-4F89-99E7-326634D1C271Q35994573-B1148107-16A4-4277-9FD6-DB584347E808Q36184041-A95F99C8-76AD-45B0-B198-9CE400CAFE21Q36589103-29689091-40C5-473F-8A4F-C3941CB178E5Q36812092-D161C392-257C-4056-A7C1-B96BDCE520ACQ37234796-9480D02E-600D-430F-AEA9-D73709BA79BEQ37404492-9CFF9BF7-7FEB-4136-BCFB-74C9161B14E6Q37686896-88B9B352-3933-4CE0-BFA3-C2DAFA53CD39Q37822362-8AEF8FFA-95C3-4D28-BD35-02E029846F7BQ38147124-B1D2F140-B309-44B7-BDCE-8C4F03C8A2A0Q39549928-A57D6F8C-3722-49F8-ACDA-480A7B4CD81AQ40140125-78C14CE0-583A-4338-BE6B-34684F632CE1Q40368393-39ACB4CC-06D4-4717-848C-A06E80BA6949Q40559301-6E6D6D4D-562F-4CEA-9779-D8F2A3A3FE5EQ40669592-3D99528C-FBDF-481A-86A1-BBFD22695A53Q40684870-22E7A1E4-83CB-468C-AF2A-9E1B8E0AB1D5Q40689787-FF088611-F151-4652-92DD-251877CA73AAQ40705119-7EEF08DE-0850-4492-A268-A11767BD1205Q40752955-FF856F93-A7A3-46E7-AE6A-9A0CFE87DC7EQ40755492-72ACC165-FE67-4A8B-9146-341C228347D5Q40839482-50E54F73-0A8D-4C6C-9BE3-B69D093FE19BQ40889346-7E71614E-8DCD-4F47-8D22-57CC40CBCCC3Q41679042-3D46C7D1-E768-4F28-B487-5EB089A7358DQ41720182-3E616DE2-D4FB-4173-AFBE-21A5FE90B20EQ42768501-67B784E0-818F-4AE5-A74C-CC7E522112DFQ43248975-E34DAF13-DF13-4663-B15C-7D8C14C445D5Q45023986-DBE66BFF-BBA8-4B79-AD82-D7CFED4AA40BQ45814147-F9DD4AEC-D74D-423D-B43E-77C6887039D1Q45863017-36F4A8D1-F001-44BE-9B18-A082A960F015Q45966374-41346F1C-327B-4ED5-A6A3-6596343087B3Q47651262-826C24ED-D9D9-4B3E-9E34-258397246783Q47686578-E8693DB9-E90A-41D2-AAEE-AD84BEE76B54Q48626345-6F9EAEF3-E148-457D-AC74-F4369300044C
P2860
NIH conference. New approaches to the immunotherapy of cancer using interleukin-2.
description
1988 nî lūn-bûn
@nan
1988年の論文
@ja
1988年論文
@yue
1988年論文
@zh-hant
1988年論文
@zh-hk
1988年論文
@zh-mo
1988年論文
@zh-tw
1988年论文
@wuu
1988年论文
@zh
1988年论文
@zh-cn
name
NIH conference. New approaches to the immunotherapy of cancer using interleukin-2.
@en
NIH conference. New approaches to the immunotherapy of cancer using interleukin-2.
@nl
type
label
NIH conference. New approaches to the immunotherapy of cancer using interleukin-2.
@en
NIH conference. New approaches to the immunotherapy of cancer using interleukin-2.
@nl
prefLabel
NIH conference. New approaches to the immunotherapy of cancer using interleukin-2.
@en
NIH conference. New approaches to the immunotherapy of cancer using interleukin-2.
@nl
P2093
P1476
NIH conference. New approaches to the immunotherapy of cancer using interleukin-2.
@en
P2093
P304
P356
10.7326/0003-4819-108-6-853
P407
P577
1988-06-01T00:00:00Z